Payment overview · 2025
General Payments
$349.89
19 reported records · 10 companies
Healthcare provider profile · identity verified
Michael Nasr Mankarious, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CLINTON, IA · NPI 1659375921
Verified facts
What the public records show
CMS Open Payments records show Michael Nasr Mankarious, M.D. received $349.89 in general payments during 2025 across 19 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ingrezza, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $91.77 | 26.2% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $59.48 | 17.0% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $40.46 | 11.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $38.67 | 11.1% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.33 | 9.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.74 | 6.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.48 | 5.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.16 | 4.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.11 | 4.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.69 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $349.89 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $59.48 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $40.46 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $38.67 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $33.33 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.98 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.28 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 74 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 117 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
117 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 739 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 664 | 135 |
| Gabapentin | Gabapentin | 526 | 88 |
| Furosemide | Furosemide | 525 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 476 | 74 |
| Omeprazole | Omeprazole | 452 | 87 |
| Montelukast Sodium | Montelukast Sodium | 426 | 77 |
| Potassium Chloride | Potassium Chloride | 397 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 365 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 320 | 69 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 273 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 253 | 49 |
| Eliquis | Apixaban | 240 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 211 | 39 |
| Ezetimibe | Ezetimibe | 207 | 41 |
| Lisinopril | Lisinopril | 204 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 43 |
| Metformin Hcl | Metformin Hcl | 183 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 158 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 157 | 57 |
| Clonazepam | Clonazepam | 155 | 34 |
| Losartan Potassium | Losartan Potassium | 153 | 33 |
| Benazepril Hcl | Benazepril Hcl | 136 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 136 | 26 |
| Prednisone | Prednisone | 130 | 67 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 122 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 16 |
| Ozempic | Semaglutide | 117 | 21 |
| Warfarin Sodium | Warfarin Sodium | 112 | 14 |
| Finasteride | Finasteride | 109 | 28 |
| Sertraline Hcl | Sertraline Hcl | 109 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 107 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 106 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 104 | 13 |
| Tramadol Hcl | Tramadol Hcl | 99 | 22 |
| Cephalexin | Cephalexin | 94 | 72 |
| Glimepiride | Glimepiride | 88 | 16 |
| Lorazepam | Lorazepam | 86 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 85 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 80 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 79 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 76 | suppressed |
| Alprazolam | Alprazolam | 75 | 11 |
| Carvedilol | Carvedilol | 75 | 14 |
| Farxiga | Dapagliflozin Propanediol | 74 | 15 |
| Xarelto | Rivaroxaban | 74 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 67 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 15 |
| Allopurinol | Allopurinol | 65 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | suppressed |
| Simvastatin | Simvastatin | 64 | 16 |
| Pregabalin | Pregabalin | 62 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 61 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 60 | suppressed |
| Spironolactone | Spironolactone | 54 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 53 | 15 |
| Amoxicillin | Amoxicillin | 52 | 34 |
| Ibandronate Sodium | Ibandronate Sodium | 51 | 11 |
| Azithromycin | Azithromycin | 50 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 50 | suppressed |
| Myrbetriq | Mirabegron | 49 | suppressed |
| Cefdinir | Cefdinir | 48 | 38 |
| Labetalol Hcl | Labetalol Hcl | 48 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 48 | 11 |
| Folic Acid | Folic Acid | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Glipizide Er | Glipizide | 46 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 46 | suppressed |
| Meloxicam | Meloxicam | 46 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | suppressed |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Nystatin | Nystatin | 43 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 13 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 42 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 12 |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Jardiance | Empagliflozin | 38 | suppressed |
| Nabumetone | Nabumetone | 38 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Methotrexate | Methotrexate Sodium | 36 | suppressed |
| Digoxin | Digoxin | 35 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Metolazone | Metolazone | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 22 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Sotalol | Sotalol Hcl | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 25 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 25 | suppressed |
| Lacosamide | Lacosamide | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Asmanex Hfa | Mometasone Furoate | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 16 |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 14 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 14 | suppressed |
| Leflunomide | Leflunomide | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Safetyglide Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Cefadroxil | Cefadroxil | 11 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Zafirlukast | Zafirlukast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $349.89 · 19 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, FARXIGA, GVOKE HYPOPEN, INGREZZA, JARDIANCE, MOUNJARO, Ozempic, SHINGRIX, VOQUEZNA, WATCHMAN Access System, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error